EyePoint Pharmaceuticals announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the company’s financial and capital markets activities.
Mr. Price brings to EyePoint more than 25 years of financial experience in the health care, investment banking, and accounting industries. He has extensive experience in executing debt and equity capital financings, business development deals, restructurings and oversight of all financial functions in both domestic and international markets for public and private commercial companies.
“We are fortunate to have someone with David’s successful track record and deep financial expertise join EyePoint Pharmaceuticals, and we welcome his significant cross-industry experience, both in investment banking and as the chief financial officer of both public and private companies,” Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals, said in a company news release. “David’s experience with mergers and acquisitions, accounting, capital raising, debt restructuring and international supply chain management will be invaluable as EyePoint evolves into a commercial-stage company in 2019, with the anticipated launches of both Dexycu and Yutiq, subject to FDA approval.”
“With two potential near-term ophthalmic product launches, a broad pipeline of ophthalmology products utilizing both the company’s Durasert and Verisome technology, and two premier partners providing capital, I believe EyePoint is positioned for success in both the near- and longer-term, and has compelling growth potential,” Mr. Price said. I look forward to working closely alongside the dynamic team at EyePoint as we strive to create shareholder value and deliver effective ophthalmic therapies to underserved patients in areas of unmet need.”